Indian Cancer Drug Manufacturers Seek 50% Price Increase as Platinum Costs Surge
Key Insights
Indian pharmaceutical companies are requesting a 50% price increase for essential platinum-based cancer (search) drugs including carboplatin, cisplatin, and oxaliplatin due to manufacturing becoming commercially unviable.
Platinum prices have nearly doubled from ₹3,869 per gram in September to ₹8,000 per gram in February, driven by geopolitical uncertainty affecting precious metals markets.
Major manufacturers including Cipla, Dr Reddy's, and Zydus warn that without government intervention, the availability of these first-line cancer (search) treatments may be threatened.
Indian pharmaceutical manufacturers are facing a critical supply crisis for essential cancer (search) medications as soaring platinum prices threaten the commercial viability of producing carboplatin, cisplatin, and oxaliplatin. Major companies including Cipla, Intas, Dr Reddy's Laboratories, Zydus Lifesciences, Emcure, Fresenius (search) and Hetero have approached the National Pharmaceutical Pricing Authority (search) seeking a 50% increase in maximum retail prices to ensure continued availability of these vital treatments.
Platinum Price Surge Creates Manufacturing Crisis
Geopolitical uncertainty has driven platinum prices to historic highs, with costs nearly doubling from ₹3,869 per gram in September to ₹8,000 per gram in February. This surge parallels increases in other precious metals including gold and silver. According to industry executives, the current ceiling price for carboplatin became commercially unviable as early as January.
The ceiling price for carboplatin currently stands at ₹61.10 per 10 mg/ml vial, while cisplatin ranges from ₹70 to ₹300 based on drug strength. These prices have been under government control since 2013, with carboplatin experiencing only a 21.71% price increase since 2015, representing a compound annual growth rate of just 2.21%.
Critical Role in Cancer Treatment
Platinum-based chemotherapy agents form the backbone of treatment protocols across multiple cancer (search) types including head and neck, breast, and gastrointestinal cancers. Dr. Pramod Kumar Julka, vice chairman of Max Oncology (search), emphasized that "platinum drugs like cisplatin and carboplatin are among the most affordable and widely accessible chemotherapy agents available."
Carboplatin has been recognized as fundamentally important in cancer (search) treatment protocols notified by the Indian Council of Medical Research and is listed as an essential medicine globally. The drug appears in the National Formulary of India 2021 and is indicated for advanced stages of ovarian cancer (search) and certain lung cancers.
Market Dynamics and Supply Concerns
According to PharmaTrac (search) market research data, the platinum-based drug market is valued at ₹110 crore and growing at 14% annually. However, industry executives suggest the actual market size could be at least ten times higher when accounting for institutional sales and direct hospital purchases, which are not fully captured in retail sales data.
An industry executive warned that "if the government does not intervene and take corrective steps in public interest, it may threaten our profitability and availability of an important first-line cancer (search) treatment." The situation creates what another executive described as a "dangerous paradox" where the low price point of these essential drugs provides little financial incentive for reliable production, despite their critical therapeutic importance.
Regulatory Precedent for Price Adjustments
The Committee on Affordable Medicines and Health Products of the Niti Aayog had previously endorsed a one-time 50% increase in ceiling prices for essential medicines facing manufacturing unviability in 2019. This precedent supports the current industry request as manufacturers struggle with the dramatic increase in raw material costs.
PharmaTrac (search) vice-president Sheetal Sapale noted that retail sales figures do not fully represent the market scope for these drugs, as significant portions involve institutional sales or direct hospital procurement. With increasing cancer (search) incidence rates, the demand for platinum-based chemotherapy agents continues to grow, making their continued availability a critical public health concern.